Adalimumab-induced asthma

Bennett, Alex; Wong, Mcm; Zain, Amir Azlan; Panayi, G. S.; Kirkham, B. W.

doi:10.1093/rheumatology/keh676

Cited by 30 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though IL-6 and TNF-alpha Oral cockroach hypoallergen prevents roach-allergic asthma in mice have been known to play important roles in asthma [32], the paradoxical change of these proinflammatory cytokines did not seem to affect the inflammatory process in the airways according to the histopathology findings in the lung as shown on Fig 7 and airway hyperresponsiveness as shown at Fig 5. Human clinical studies using anti-TNF alpha inhibitors did not show clinical efficacy. There were even reports regarding etanercept and adalimumab -induced asthma for patients using these TNF-alpha inhibitors for other indications [33][34][35][36][37].…”

Section: Discussionmentioning

confidence: 99%

Oral edible plant vaccine containing hypoallergen of American cockroach major allergen Per a 2 prevents roach-allergic asthma in a murine model

Lee

Chiang

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundAmerican cockroaches (Periplaneta americana) are an important indoor allergen source and a major risk factor for exacerbations and poor control of asthma. We previously reported that allergen components from American cockroaches exhibit varying levels of pathogenicity. Sensitization to major American cockroach allergen, Per a 2, correlated with more severe clinical phenotypes among patients with allergic airway diseases.Materials and methodsIn this study, we examined whether oral plant vaccine-encoding full-length Per a 2 clone-996 or its hypoallergenic clone-372 could exert a prophylactic role in Per a 2-sensitized mice. The cDNAs coding Per a 2–996 and Per a 2–372 were inserted into TuMV vector and expressed in Chinese cabbage. Adult female BALB/c mice were fed with the cabbage extracts for 21 days and subsequently underwent two-step sensitization with recombinant Per a 2.ResultsPer a 2-specific IgE measured by in-house ELISA in the sera of Per a 2-372-treated groups were significantly lower than in the control groups after allergen challenge but not the Per a 2-996-treated group. Moreover, Per a 2–372 vaccine markedly decreased airway hyper-responsiveness and infiltration of inflammatory cells into the lungs, as well as reduced mRNA expression of IL-4 and IL-13 in comparison with the control mice.ConclusionOur data suggest that oral administration of edible plant vaccine encoding Per a 2 hypo-allergen may be used as a prophylactic strategy against the development of cockroach allergy.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral edible plant vaccine containing hypoallergen of American cockroach major allergen Per a 2 prevents roach-allergic asthma in a murine model

Lee

Chiang

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…As previously reported [29-31], methotrexate was the most frequently used ISD in our cohort. These therapies seemed to be well tolerated, as only in 1 patient a severe adverse reaction caused discontinuation (bronchospasm in 1 patient treated with adalimumab [32]). In addition, clinical efficacy was the most frequent cause for discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Disease Remission in Children and Adolescents with Intermediate Uveitis: A Survival Analysis

et al. 2017

View full text Add to dashboard Cite

Purpose: To report the incidence rate (IR) of remission in pediatric noninfectious intermediate uveitis (IU). Methods: Longitudinal retrospective cohort study, including 19 patients (32 eyes) between 1985 and 2014, followed-up until loss or January 2016. Remission was defined following the Standardization of Uveitis Nomenclature workshop criteria, prolonged remission as a remission spanning 12 months and until the end of follow-up, and relapse as recurrence of inflammatory activity in an eye in remission. Results: Median follow-up time was 6.3 years. IRs (95% confidence interval) for remission, relapse, and prolonged remission were 18.6 (13.1–26.5), 32.3 (20.6–50.7), and 6.7 (3.8–11.9) episodes per 100 eye-years, respectively. 48% of eyes relapsed in the first year following remission. 25 and 50% of eyes achieved prolonged remission after 5 and 10 years of follow-up, respectively. Conclusions: Inflammatory relapses may be frequent in noninfectious IU affecting children and adolescents, appearing early after remission. Also, prolonged remission seems infrequent, being achieved late during follow-up.

show abstract

“…A possible explanation of the new onset of asthma in these patients lies in the contrasting inflammatory responses in RA compared with asthma and other allergic diseases. Bennett et al (2) suggested an involvement of T helper 1/ T helper 2 balance in the side effects of anti-TNF-α, with a Th1 cytokine decrease, allowing Th2 to be expressed, leading to asthma symptoms. We hypothesize that active RA in this case produced a Th1 cytokine response, which suppressed the clinical expression of asthma.…”

Section: Discussionmentioning

confidence: 99%

“…Asthma appears to be a definite but rare side-effect of anti-TNF blockade . Asthma symptoms appeared after introduction of anti-TNF-α in two patients who did not appear to be predisposed to the disease (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%